The U.S. Food and Drug Administration (FDA) recently announced that they will be delaying the enforcement of upcoming supply chain regulations for drugs till 2024. The requirements were originally set to come into force in November 2023.
The delay was formally declared in a guidance document published by the FDA. As per their explanation, this one-year reprieve is intended to allow industry players more time to meet certain obligations. These obligations cover crucial areas such as interoperable, electronic, and package-level product tracing requirements, which are intended to enhance the integrity and security of the pharmaceutical supply chain.
The FDA’s decision might have relieved the pharmaceutical industry, who have been grappling with various challenges in their supply chain mechanisms. However, the delay also underscores the complexity of implementing an electronic and interoperable drug tracking capability at the package level, which could enable real-time responses to drug recalls and enhance detection and removal of counterfeit drugs.
As indicated by Jones Day, a law firm specializing in various aspects of corporate law, the onus of meeting these obligations leans heavily on the pharmaceutical industry. The delay has indeed bought more time for these companies, but they must also brace themselves for the rigorous implementation of these requirements within the new time frame.
For more detailed information, visit Jones Day’s commentary on this topic.